Deals In Depth: September 2013
Biogen and Isis teamed up for the fourth time in a new deal worth $450 million, focused on CNS disorders; Stryker gained robotic-assisted surgery expertise in its $1.4 billion acquisition of MAKO Surgical. Biopharma financing more than doubled in September compared with the previous month, reaching $1.7 billion and boosted by KV Pharma’s $375 million offering; device fundraising also increased, to $205 million, driven by early-stage venture rounds.
You may also be interested in...
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.